Skip to main content
Case Study

Science 37 Accelerates Oncology Clinical Trial Timeline by 3 Years

A biopharma company was investigating how its diagnostic screening technology—a one-time blood sample—performed against the gold-standard cancer screening procedure.

The protocol required 25,000 average-risk patients between the ages of 45 and 85 to enroll. The sponsor also looked to include a diverse and representative population in the trial.

See how the Science 37 Metasite™ enrolled nearly 50% of the entire study with 24.2% minority representation, enabling recruitment and access across 49 states. This accelerated approach resulted in a more than 3-year reduction of the clinical trial timeline.

Submit the form to watch the case study video.